


Redefining respiratory care:

Our commitment to prevent, treat and stop disease progression through innovation

NP-GB-RS-COCO-250004 This document has been created and funded by GSK. Date of Preparation: June 2026



At GSK, we believe in **getting ahead of respiratory disease together** to benefit people with respiratory disease, communities, the NHS, the environment and the economy.

Today, respiratory and pulmonary conditions are in the top six causes of death in the UK[1,2]. Between 2013 and 2019, an average of 68,000 people a year died from respiratory disease in England, equivalent to 1 person every 8 minutes[3]. Respiratory conditions often come with distressing symptoms like cough, breathlessness and fatigue. For some people with long term conditions, these symptoms can get worse over time, leading to stigma, social isolation and loneliness[4].

That's why for more than five decades, **we have been at the forefront of the most complex respiratory health challenges,** working to prevent disease progression and ensure all patients have access to innovative treatment options.

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and chronic obstructive pulmonary disease (COPD).

Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation treatments that work in distinct ways to help as many patients as possible. We continue to pursue the most ambitious treatment goals, aiming for early interventions that prevent, treat and stop disease, limiting future complications for patients.

This document has been created and funded by GSK.

Our long-standing commitment to innovation in the UK

1958

Glaxo Laboratories Ltd. acquire Allen & Hanburys Ltd leading to the creation of a **new R&D team working on respiratory innovation.**

2009

A multidisciplinary group of international experts in COPD, supported by GSK, launch the **COPD Assessment Test (CAT)** as a tool to help improve disease management.

2012

GSK launches the first-of-its-kind **'Complete the Cycle' programme** to help people recycle their empty inhalers and keep waste out of landfill.

2013

GSK launches **£50 million** venture capital fund to invest in **pioneering bioelectronic medicines and technologies,** including for asthma and COPD.

2016

GSK invests **£250 million in state-of-the-art manufacturing facilities** in Barnard Castle in County Durham, Montrose in Angus, and Ware in Hertfordshire, which play a role in manufacturing our respiratory medicines.

2018

GSK begins funding a non-promotional **COPD Patient Review Service** which partners with the NHS by supporting practices to deliver COPD reviews.

2018

GSK becomes a founding funder of the **Taskforce for Lung Health,** a coalition of over 50 organisations and individuals. The Taskforce's mission is to prevent more people from developing lung disease and to transform the care of people living with lung disease in England.

2023

GSK begins testing an alternative propellant which has the potential to **reduce greenhouse gas emissions from our inhalers,** without compromising health outcomes.

2024

GSK, Cambridge University and Cambridge University Hospitals announce the **Cambridge-GSK Translational Immunology Collaboration,** a new five-year collaboration in kidney and respiratory disease.

Today

- GSK respiratory products are used by approximately **1.5 million people** in the UK.[5]
- Our pipeline includes **medicines and vaccines** with different modes of action for a **wide-range of respiratory diseases.**
- Our respiratory medicines are manufactured in Barnard Castle (County Durham), Montrose (Angus), and Ware (Hertfordshire) and **exported globally.**
- We have conducted more than **60 years of respiratory R&D** in the UK.

2025

GSK becomes a founding partner of the **Camden Breathing Better initiative.**

This document has been created and funded by GSK.
NP-GB-RS-COCO-250004

We are pushing the boundaries of science and technology to redefine respiratory care

and explore how we can prevent, treat and stop disease by:


Moving beyond symptom control by targeting the root cause of disease in several chronic respiratory diseases.

Developing a sustainable pathway for our metered dose inhalers which has the potential to reduce greenhouse gas emissions.

Tackling gaps in respiratory care by investing in research and development in areas of high unmet medical need.

Putting health at the centre of action on climate, given the long-term impact of air pollution on the lungs which aggravates conditions like asthma and leads to cardiovascular and respiratory diseases – as well as lung cancer.[6]

Working to make ambitious treatment goals a reality for people with respiratory conditions by researching evidence-based management strategies.



We continue to **deepen our understanding** of respiratory science and invest in the discovery and development of best-in-class vaccines and medicines. Our research will continue to **redefine what's possible in the management of respiratory health** – to protect from infections and associated complications, modify the course of disease and **help people breathe easier.**

This document has been created and funded by GSK.

Our partnerships with the NHS and the respiratory community

We want to continue to collaborate with the NHS to support respiratory services in delivering high-quality patient care and to engage with the Government to inform policies affecting respiratory health.

COPD Patient Review Service

Since 2018, GSK has funded a **COPD Patient Review Service** which partners with the NHS by supporting practices to deliver COPD reviews.

The service is delivered by third party independent pharmacists and **provides patients with a full medication review and guidance on how to manage their condition,** optimising both pharmacological and non-pharmacological treatment in line with local and national guidelines.

Since the service began, **GSK has supported over 160,000 COPD Patient Reviews** across more than 2,500 GP practices, increasing the number of patients seen in clinics and the number of COPD reviews and inhaler technique assessments delivered by GP practices[7,8].

Of the patients (23,808)[7] reviewed by the COPD Patient Review Service in 2024

30% had no recorded COPD review in the prior 12 months [8]

90% had at least one significant long-term co-morbidity [8]

64% did not have a documented record of an inhaler technique assessment in the prior 12 months [8]

22% of patients seen in clinic required treatment escalation of their inhaled therapy this demonstrates that almost ¼ of patients required an intervention to improve symptom burden management or reduce exacerbation severity/frequency [8]

80% received a non-pharmacological intervention [8]

53% of smokers said post-review they were ready to stop smoking or thinking about stopping smoking [8]

Project UNITE


Identifying and reviewing patients with uncontrolled asthma in primary care

Our joint working programme with Hampshire and Isle of Wight ICS, **Project UNITE,** aimed to **identify and review patients with uncontrolled asthma within primary care.** It facilitated referral to severe asthma services to improve access to biologics for appropriate patients with severe asthma. The project ran from October 2022 until December 2024. Virtual primary care reviews were completed by March 2024 and tertiary care reviews were completed by December 2024.

This resulted in:

73% of patients reviewed receiving a full personalised asthma action plan

98% of those needing to be referred to severe asthma clinics requiring clinical review.[9]



This document has been created and funded by GSK.
NP-GB-RS-COCO-250004

Supporting specialist asthma services to reduce waiting times

From September 2023 to September 2025, we launched a non-promotional service designed to **support NHS specialist asthma sites to reduce waiting times.** This service deploys appropriately trained respiratory nurse specialists to Severe Asthma Centres with the greatest healthcare need.

GSK supported:

6 secondary care sites right across the UK

2180 patients reached

432 clinic days delivered[10]

Cambridge-GSK Translational Immunology Collaboration

In 2024, GSK announced investment of £50 million to launch the **Cambridge-GSK Translational Immunology Collaboration (CG-TIC),** a five-year collaboration with the University of Cambridge and Cambridge University Hospitals.

The collaboration is focused on understanding the onset of a disease, its progression, how patients respond to therapies and developing biomarkers for rapid diagnosis.

Ultimately, the goal is to trial more effective, personalised medicines. It will focus on kidney and respiratory disease[11].

ALERT


Supporting diagnosis of COPD

In 2025, we launched **ALERT** (Assessment of patients to support Lung health, diagnosis and Evaluating patients from Review to Treatment support and education), a joint working programme targeting **people who have taken part in the national lung cancer screening programme** with signs and symptoms of COPD to be given a **spirometry test** by nurses to support diagnosis. Once diagnosed, patients consult with pharmacists to optimise their care and medication.

GSK SPARROW

Highlighting innovative research aimed at enhancing patient care

GSK SPARROW is a long-term initiative that offers **emerging experts the opportunity to present their work to leading figures in the respiratory field,** to develop relevant professional networks and highlight innovative research aimed at enhancing patient care.



This document has been created and funded by GSK.

References

1. Office for National Statistics, 2024. Deaths registered in England and Wales: 2023. Available at https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationsummarytables/2023. Accessed June 2026.
2. The Scottish Public Health Observatory. Available at Most frequent causes - Scot PHO. Accessed June 2026.
3. UK Government, 2022. Air pollution: Applying All Our Health. Available at https://www.gov.uk/government/publications/air-pollution-applying-all-our-health/air-pollution-applying-all-our-health. Accessed June 2026.
4. Asthma + Lung UK, 2023. Why we should be thinking about the social impact of living with a lung condition. Available at https://www.asthmaandlung.org.uk/blog/research/why-should-we-be-thinking-about-social-impact-living-lung-condition. Accessed June 2026.
5. Data on File. GPrX GP Practice Prescribing Data (2026)
6. UK Government, 2022. Air pollution: Applying All Our Health. Available at https://www.gov.uk/government/publications/air-pollution-applying-all-our-health/air-pollution-applying-all-our-health. Accessed June 2026.
7. Data on file, 2026, REF-288772.
8. Data on file, 2026, REF-288770.
9. GSK, 2025. Summary of the UNITE Service: A severe asthma patient identification, review, and referral Joint Working project between Hampshire and Isle of Wight Integrated Care System (ICS) and GlaxoSmithKline UK Ltd (GSK). NP-GB-ASU-BRFS-250003. Accessed June 2026.
10. Data on file, 2026, REF-295324.
11. Cambridge University, 2024. Cambridge and GSK announce new five-year collaboration aiming for improved outcomes for patients with hard-to-treat kidney and respiratory diseases. Available at https://www.cam.ac.uk/news/cambridge-and-gsk-announce-new-five-year-collaboration-aiming-for-improved-outcomes-for-patients. Accessed June 2026.



This document has been created and funded by GSK.